Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TPST files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTempest Therapeutics loses three board directors in single-day mass resignation
Filed May 22, 2026 · Period ending May 22, 2026 · ~1 min read
Key Changes
-
high
Stephen Brady, Michael Raab, and Christine Pellizzari all resigned from the board on May 22, 2026, with no stated disagreement. Simultaneous departures of multiple directors often signal governance upheaval or strategic pivots.
Item 5.02 verify on EDGAR → -
medium
All three departing directors waived their accrued and unpaid retainer fees, suggesting either cash constraints at the company or negotiated exit terms. This reduces immediate cash obligations.
Separation Agreements verify on EDGAR → -
low
Departing directors retain their stock options and shares, with indemnification protection continuing for six years post-separation, which is standard practice for former board members.
Separation Agreements verify on EDGAR →
Summary
Tempest Therapeutics experienced a significant governance event on May 22, 2026, when three of its board directors resigned on the same day.
While the company states there were no disagreements on operations, policies, or practices, the simultaneous departure of multiple directors is unusual and typically indicates either a strategic shift, governance restructuring, or internal challenges that aren't being publicly disclosed.
The fact that all three directors agreed to waive their unpaid retainer fees adds another layer of concern—this could signal cash flow issues or suggest the directors negotiated other favorable terms not disclosed in the filing. For retail investors, this is a yellow flag that warrants close attention. Board stability is crucial for small biotech companies like Tempest, and losing three directors at once reduces oversight and institutional knowledge. Watch for the company's next proxy filing or investor update to see who replaces these directors and whether management provides any additional context about the strategic direction. If the company struggles to attract qualified replacements or if more departures follow, it could indicate deeper problems.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Three board directors resigned simultaneously on May 22, 2026, waiving unpaid retainer fees; no disagreement with company stated.
Added in current filing · verify on EDGAR →
On May 22, 2026, each of Mr. Stephen Brady, Mr. Michael Raab and Ms. Christine Pellizzari notified Tempest Therapeutics, Inc. (the “Company”) of his or her resignation from the Board of Directors of the Company (the “Board”), effective as of such date.
Three directors resigned from the board on the same day. The company states these resignations were not due to any disagreement with the company on operations, policies, or practices. Simultaneous departures of multiple directors can signal governance changes or strategic shifts, though the company provides no specific reason for the timing.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 24, 2026 · How we verify